IRIS
BOSSI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.801
NA - Nord America 3.331
SA - Sud America 1.425
EU - Europa 588
AF - Africa 120
OC - Oceania 5
Totale 10.270
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.277
US - Stati Uniti d'America 3.173
BR - Brasile 1.219
CN - Cina 738
VN - Vietnam 250
IT - Italia 165
HK - Hong Kong 146
GB - Regno Unito 95
IN - India 91
DE - Germania 85
CA - Canada 79
AR - Argentina 77
MX - Messico 56
BD - Bangladesh 49
ZA - Sudafrica 48
EC - Ecuador 40
TR - Turchia 37
ES - Italia 35
ID - Indonesia 35
PL - Polonia 29
RU - Federazione Russa 28
JP - Giappone 25
VE - Venezuela 25
FR - Francia 22
UZ - Uzbekistan 22
IQ - Iraq 21
SE - Svezia 21
UA - Ucraina 21
CO - Colombia 20
NL - Olanda 20
MA - Marocco 18
PK - Pakistan 16
CL - Cile 15
KE - Kenya 14
FI - Finlandia 12
TN - Tunisia 12
PY - Paraguay 10
SA - Arabia Saudita 10
AE - Emirati Arabi Uniti 9
UY - Uruguay 9
AT - Austria 8
IR - Iran 8
LT - Lituania 8
EG - Egitto 7
IE - Irlanda 7
JO - Giordania 7
NP - Nepal 7
PE - Perù 7
PH - Filippine 7
TW - Taiwan 7
ET - Etiopia 6
AL - Albania 5
IL - Israele 5
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
DZ - Algeria 4
GE - Georgia 4
HU - Ungheria 4
JM - Giamaica 4
KZ - Kazakistan 4
AM - Armenia 3
AU - Australia 3
BB - Barbados 3
BH - Bahrain 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
QA - Qatar 3
TT - Trinidad e Tobago 3
BE - Belgio 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
GD - Grenada 2
HR - Croazia 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
NG - Nigeria 2
OM - Oman 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
NI - Nicaragua 1
NR - Nauru 1
PA - Panama 1
PR - Porto Rico 1
PW - Palau 1
Totale 10.266
Salva come PNG Salva come JPEG
Città #
Singapore 948
The Dalles 896
Shanghai 515
Dallas 483
Ashburn 373
Beijing 147
Hong Kong 136
Ho Chi Minh City 103
São Paulo 98
Seattle 86
Los Angeles 77
New York 52
Hanoi 47
Santa Clara 47
Johannesburg 36
Rio de Janeiro 36
Boardman 35
Assago 34
Milan 34
Atlanta 33
Curitiba 32
Montreal 32
Munich 30
Naples 28
Brooklyn 27
San Francisco 27
Warsaw 27
Council Bluffs 24
Belo Horizonte 22
Mexico City 22
Tashkent 22
Campinas 21
Tokyo 21
Brasília 20
Chicago 20
London 20
Stockholm 19
Phoenix 18
Boston 17
Chennai 17
Orem 17
Ribeirão Preto 17
Secaucus 16
Denver 15
Guayaquil 15
Buffalo 14
Poplar 14
Goiânia 13
Nairobi 13
Chandler 12
Mumbai 12
Ankara 11
Manchester 11
New Delhi 11
Porto Alegre 11
Quito 11
Salvador 11
Caracas 10
Dhaka 10
Fortaleza 10
Toronto 10
Charlotte 9
Haiphong 9
Santo André 9
Vancouver 9
Amsterdam 8
Betim 8
Düsseldorf 8
Helsinki 8
Jakarta 8
Karachi 8
Montevideo 8
Sorocaba 8
Tunis 8
Volta Redonda 8
Biên Hòa 7
Blumenau 7
Bogotá 7
Buenos Aires 7
Caxias do Sul 7
Cotia 7
Dublin 7
Guarulhos 7
Houston 7
Hải Dương 7
Las Vegas 7
Manaus 7
Nuremberg 7
Osasco 7
Piracicaba 7
Reston 7
Santiago 7
São Bernardo do Campo 7
Vitória da Conquista 7
Addis Ababa 6
Asunción 6
Bengaluru 6
Canoas 6
Genoa 6
Mauá 6
Totale 5.231
Salva come PNG Salva come JPEG
Nome #
New trends in supportive care of head and neck cancers 94
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis 89
Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis 78
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 76
Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck 74
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6 69
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer 67
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 65
Role of Radiotherapy in the management of metastases from salivary gland carcinoma. 54
USO DI MIRNA COME BIOMARCATORI PER LA DIAGNOSI E PROGNOSI DEL CARCINOMA ORALE A CELLULE SQUAMOSE 51
The Use of Artificial Intelligence in Head and Neck Cancers: A Multidisciplinary Survey 46
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact 46
Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis 45
A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy 45
Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT) 45
Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study 43
A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer 43
ESMO Guidelines: Cancer patient management during the COVID-19 pandemic 43
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 42
Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety 40
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 39
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 39
A case of otoliquorrhoea secondary to immunotherapy response in head and neck cutaneous squamous cell carcinoma. When abrupt response may worry the physician 38
Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma 38
Editorial: Understanding and treating rare nasal and paranasal sinus cancers 37
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy 37
A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes 37
A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity 37
A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches 37
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of Aqualief™ mucoadhesive tablets in head and neck cancer patients who developed radiation-induced xerostomia 37
A European survey on the practice of nutritional interventions in head–neck cancer patients undergoing curative treatment with radio(chemo)therapy 36
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial 36
A NATURAL HISTORY OF A SERIES OF RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC) 36
Computer Vision Foundation Models in Endoscopy: Proof of Concept in Oropharyngeal Cancer 36
A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients 36
International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma 35
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 35
Diving into hot topics of salivary gland carcinoma management—an EORTC young and early career investigator survey 35
Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents 35
A complete remission with androgen-deprivation therapy in a recurrent androgen recptor-expressing adenocarcinoma of the parotid gland [1] 34
Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015 34
Precision medicine in head and neck cancer: from immunotherapy to microbiota, circulating DNA and robotic surgery 34
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort 34
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports 33
Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework 33
The 2024 International Society of Oral Oncology-Multinational Association of Supportive Care in Cancer-American Society of Clinical Oncology guidelines for the prevention and management of osteoradionecrosis of the jaw 33
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 33
A ct-based radiomic signature can be prognostic for 10-months overall survival in metastatic tumors treated with nivolumab: An exploratory study 33
Patterns of Failure after Intensity Modulated Radiation Therapy (IMRT) and Chemotherapy for Patients with Nasopharyngeal Carcinoma 33
HoW reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group (vol 152, 106744, 2024) 32
Sinonasal Malignancies of Anterior Skull Base Histology-driven Treatment Strategies 32
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 31
Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma 31
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 31
New insights in chemotherapy 31
The use of fentanyl in pain management in head and neck cancer patients: a narrative review 31
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines 31
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab 30
Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic 30
Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up 30
Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a nonendemic area 30
Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer 30
Treatment Options for Recurrent Anterior Skull Base Tumors 30
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs) 30
Treatment and outcome of metastatic parathyroid carcinoma: A systematic review and pooled analysis of published cases 30
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 29
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 29
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 29
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy 29
Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study) 29
Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? 29
Nodal status in major salivary gland cancer: External validation of a novel N- classification 29
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines 29
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands 29
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 29
Fragile Histidine Triad Gene Inactivation in Lung Cancer The European Early Lung Cancer Project 29
Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action 29
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma 29
Bridging gaps in cancer cachexia Care: Current insights and future perspectives 29
Quality Assessment in Supportive Care in Head and Neck Cancer 29
Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? 28
Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers 28
Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods 28
Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling 28
A multidisciplinary approach to squamous cell carcinomas of the head and neck: What is new? 28
The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity 28
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review 28
Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding 28
What to do and what not to do in the management of cancer pain: A physician survey and expert recommendations 28
The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours 28
Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study 28
May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer? 28
Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy 28
PROGNOSTIC FACTORS INFLUENCING OUTCOME OF PATIENTS WITH RECURRENT OR METASTATIC CARCINOMA (RandM) OF THE HEAD AND NECK: RESULTS OF AN ITALIAN MONOINSTITUTIONAL STUDY 28
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab 28
TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC) 28
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients 27
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 27
Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: Consensus statements from an Italian expert panel 27
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy 27
Totale 3.666
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.532
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.532
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 3 1 1 2 1 0 2
2021/20224 0 0 0 2 0 0 0 1 0 0 1 0
2022/202334 4 0 2 4 5 3 0 1 11 2 1 1
2023/20241.254 2 2 6 0 0 0 1 434 43 53 251 462
2024/20254.244 138 26 56 86 45 395 214 189 825 1.141 533 596
2025/20265.187 1.797 902 705 992 466 325 0 0 0 0 0 0
Totale 10.733